The current stock price of EMMA is 2.77 null. In the past month the price decreased by -30.75%.
ChartMill assigns a fundamental rating of 3 / 10 to EMMA. Both the profitability and financial health of EMMA have multiple concerns.
Over the last trailing twelve months EMMA reported a non-GAAP Earnings per Share(EPS) of -11.16. The EPS increased by 26.19% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | -729.66% | ||
| ROA | -220.74% | ||
| ROE | -570.03% | ||
| Debt/Equity | 0.37 |
Emmaus Life Sciences Inc. is a commercial-stage biopharmaceutical company. It is engaged in the discovery, development, marketing and sale of treatments and therapies, for rare and orphan disease categories. Emmaus Life Sciences Inc., formerly known MYnd Analytics Inc., is based in Torrance, United States.
Emmaus Life Sciences Inc.
21250 Hawthorne Boulevard Suite 800
Torrance CA 90503
CEO: George C. Carpenter
Phone: 310-214-0065
Emmaus Life Sciences Inc. is a commercial-stage biopharmaceutical company. It is engaged in the discovery, development, marketing and sale of treatments and therapies, for rare and orphan disease categories. Emmaus Life Sciences Inc., formerly known MYnd Analytics Inc., is based in Torrance, United States.
The current stock price of EMMA is 2.77 null. The price decreased by -38.31% in the last trading session.
EMMA does not pay a dividend.
EMMA has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Emmaus Life Sciences Inc. (EMMA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-11.16).
Emmaus Life Sciences Inc. (EMMA) has a market capitalization of 131.48M null. This makes EMMA a Micro Cap stock.